These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28109167)

  • 1. Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities.
    Haass NK; Gabrielli B
    Exp Dermatol; 2017 Jul; 26(7):649-655. PubMed ID: 28109167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
    Johnson DB; Sosman JA
    JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging targeted therapies for melanoma.
    Johnson DB; Pollack MH; Sosman JA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-Time Cell Cycle Imaging in a 3D Cell Culture Model of Melanoma.
    Spoerri L; Beaumont KA; Anfosso A; Haass NK
    Methods Mol Biol; 2017; 1612():401-416. PubMed ID: 28634959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MAPK pathway in melanoma therapy.
    Cheng Y; Zhang G; Li G
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
    Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs.
    Maira F; Catania A; Candido S; Russo AE; McCubrey JA; Libra M; Malaponte G; Fenga C
    Curr Drug Deliv; 2012 Jan; 9(1):17-29. PubMed ID: 22023213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What's new in skin cancers?].
    Jouary T
    Ann Dermatol Venereol; 2014 Dec; 141 Suppl 4():S630-42. PubMed ID: 25539755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell Cycle Regulation and Melanoma.
    Xu W; McArthur G
    Curr Oncol Rep; 2016 Jun; 18(6):34. PubMed ID: 27106898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
    Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
    Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
    Lau PK; Ascierto PA; McArthur G
    Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinases as therapeutic targets in melanoma.
    Miller DM; Flaherty KT
    Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy for metastatic melanoma: an overview and update.
    Boyle GM
    Expert Rev Anticancer Ther; 2011 May; 11(5):725-37. PubMed ID: 21554048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major therapeutic developments and current challenges in advanced melanoma.
    Sullivan RJ; Flaherty KT
    Br J Dermatol; 2014 Jan; 170(1):36-44. PubMed ID: 24443912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.